Statins Linked to Lower Dementia Risk, FDA Approves First Daily Cholesterol Pill
New health news is connecting cholesterol care, brain health and medication access. A 15-year Danish registry study presented at ESC Congress 2026 found that adults with newly diagnosed type 2 diabetes who began statins within a year had an approximately 15% lower relative risk of dementia over 10 years than those who did not start treatment early.
The findings are significant because people with type 2 diabetes already face elevated cardiovascular and dementia risks. However, the study was observational. It shows an association: not proof that statins prevent dementia: and further research is needed.
There is also a new option for people who need additional LDL cholesterol reduction. The FDA approved Merck’s Lipfendra (enlicitide), the first oral PCSK9 inhibitor. Taken once daily with diet and exercise, the tablet is approved for adults with high cholesterol, including some people with inherited heterozygous familial hypercholesterolemia. In clinical trials, LDL levels fell by about 56% to 59% at 24 weeks compared with placebo.
Meanwhile, Medicare’s GLP-1 Bridge pilot offers eligible Part D beneficiaries certain weight-loss GLP-1 medications for $50 per month through December 2027. But strict BMI, coverage and medical criteria apply. Some high-need seniors: including people whose treatment falls under existing coverage pathways: may not qualify, and the copay does not count toward Part D out-of-pocket costs.
For lifestyle trends and health updates, follow Brownstone Worldwide’s latest coverage. Talk with a clinician before starting, stopping or changing medication, and contact Medicare at 1-800-MEDICARE to check eligibility. How are these developments affecting health conversations in your neighborhood?
